

## **SUMMARY OF PRODUCT CHARACTERISTICS**

### **1. NAME OF THE VETERINARY MEDICINAL PRODUCT**

Nerfasin 100 mg/ml solution for injection for cattle and horses

### **2. QUALITATIVE AND QUANTITATIVE COMPOSITION**

Each ml contains:

#### **Active substance:**

Xylazine 100 mg  
(equivalent to 116.55 mg xylazine hydrochloride)

#### **Excipients:**

| <b>Qualitative composition of excipients and other constituents</b> | <b>Quantitative composition if that information is essential for proper administration of the veterinary medicinal product</b> |
|---------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------|
| Methyl parahydroxybenzoate (E218)                                   | 1.0 mg                                                                                                                         |
| Sodium hydrogen carbonate (for pH-adjustment)                       |                                                                                                                                |
| Hydrochloric acid (for pH-adjustment)                               |                                                                                                                                |
| Water for injections                                                |                                                                                                                                |

Clear, colourless solution.

### **3. CLINICAL INFORMATION**

#### **3.1 Target species**

Cattle ( $\geq 200$  kg) and horses.

#### **3.2 Indications for use for each target species**

Sedation.

Premedication in combination with an anaesthetic.

See also section 3.3 "Contraindications".

#### **3.3 Contraindications**

- Do not use in cases of hypersensitivity to the active substance or to any of the excipients.
- Do not use in animals with gastrointestinal obstruction as the muscle relaxant properties of the drug appear to accentuate the effects of the obstruction and because of possible vomiting.

- Do not use in animals with severe renal or hepatic impairment, respiratory dysfunction, cardiac abnormalities, hypotension and/or shock.
- Do not use in diabetic animals.
- Do not use in animals with a history of seizures.
- Do not use in cattle with a body weight of less than 200 kg. Do not use in foals younger than 2 weeks.
- Do not use during the last stage of pregnancy (danger of premature birth), except at parturition (see section 3.7 “Use during pregnancy, lactation or lay”).

### 3.4 Special warnings

#### Horses:

- Xylazine inhibits the normal intestinal motility. Therefore, it should only be used in horses with colic, that are not responsive to analgesics. The use of xylazine should be avoided in horses with caecal malfunction.
- After treatment of horses with xylazine, the animals are reluctant to walk, so whenever possible the veterinary medicinal product should be administered in the place where the treatment/investigation is going to take place.
- Caution should be taken in the administration of the veterinary medicinal product to horses susceptible to laminitis.
- Horses with airway disease or malfunction may develop life-threatening dyspnoea.
- The dose should be kept as low as possible.
- The association with other pre-anaesthetic agents or anaesthetic agents should be the subject of a benefit-risk assessment. This assessment should consider the composition of the veterinary medicinal products, their dose and the nature of the surgery. Recommended dosages are likely to vary according to the choice of the anaesthetic association.

#### Cattle:

- Ruminants are highly susceptible to the effects of xylazine. Normally cattle remain standing at the lower doses, but some animals may lie down. At the highest recommended doses most animals will lie down and some animals may lapse in lateral recumbency.
- Reticulo-ruminal motor functions are depressed after injection of xylazine. This may results in bloat. It is advisable to withhold feed and water for several hours before administration of xylazine.
- In cattle the ability to eructate, cough and swallow is retained but reduced during the period of sedation, therefore cattle must be closely watched during the recovery period: the animals should be maintained in sternal recumbency.
- In cattle life threatening effects may occur after intramuscular doses above 0.5 mg/kg body weight (respiratory and circulatory failure). Therefore very precise dosing is required.

- This veterinary medicinal product should only be used in cattle weighing 200 kg or more. Since it is highly concentrated, a slight deviation from the actual volume to be injected may cause serious adverse reactions. In case cattle weighing less than 200 kg need to be treated, xylazine with a lower strength should be used (e.g. 20 mg/ml).
- The association with other pre-anaesthetic agents or anaesthetic agents should be the subject of a benefit-risk assessment. This assessment should consider the composition of the veterinary medicinal products, their dose and the nature of the surgery. Recommended dosages are likely to vary according to the choice of the anaesthetic association.

### **3.5 Special precautions for use**

#### Special precautions for safe use in the target species:

- Keep the animals calm, because they may respond to external stimuli.
- Avoid intra-arterial administration.
- Tympany may occasionally occur in recumbent cattle and can be avoided by maintaining the animal in sternal recumbency.
- To avoid aspiration of saliva or food, lower the animal's head and neck. Fast the animals before use of the veterinary medicinal product.
- Older and exhausted animals are more sensitive to xylazine, whilst nervous or highly excitable animals may require a relatively high dose.
- In case of dehydration, xylazine should be used cautiously.
- Do not exceed the recommended dosage.
- Following administration animals should be allowed to rest quietly until the full effect has been reached.
- It is advised to cool animals when the ambient temperature is above 25°C and to keep animals warm at low temperatures.
- For painful procedures, xylazine should always be used in combination with local or general anaesthesia.
- Xylazine produces a certain degree of ataxia; therefore, xylazine must be used cautiously in procedures involving the distal extremities and in standing castrations in the horse.
- Treated animals should be monitored until the effect has faded totally (e.g. cardiac and respiratory function, also in the post-operative phase) and should be segregated to avoid bullying.

#### Special precautions to be taken by the person administering the veterinary medicinal product to animals:

- Care should be taken to avoid accidental self-injection. In case of accidental oral intake or self-injection, seek medical advice immediately and show the package leaflet or the label to the physician but DO NOT DRIVE as sedation and changes in blood pressure may occur.
- Avoid skin, eye or mucosal contact.

- Wash the exposed skin immediately after exposure with large amounts of water.
- Remove contaminated clothes that are in direct contact with skin.
- In case of accidental contact of the veterinary medicinal product with eyes, rinse abundantly with fresh water. If symptoms occur, seek the advice of a physician.
- If pregnant women handle the veterinary medicinal product, special caution should be observed not to self-inject as uterine contractions and decreased foetal blood pressure may occur after accidental systemic exposure.

To the physician:

Xylazine is an  $\alpha 2$ -adrenoreceptor agonist, symptoms after absorption may involve clinical effects including dose-dependent sedation, respiratory depression, bradycardia, hypotension, a dry mouth and hyperglycaemia. Ventricular arrhythmias have also been reported. Respiratory and haemodynamic symptoms should be treated symptomatically.

Special precautions for the protection of the environment:

Not applicable.

### 3.6 Adverse events

Cattle:

|                                                                                      |                                                                                                                                                                                                                                                                      |
|--------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Very rare<br>( $<1$ animal / 10,000 animals treated,<br>including isolated reports): | Bradycardia, arrhythmia <sup>a</sup> , hypotension<br>Hypothermia <sup>b</sup> , hyperthermia <sup>b</sup><br>Respiratory depression, respiratory arrest,<br>stridor (nasal)<br>Hypersalivation (profound), tongue<br>disorder <sup>c</sup> , regurgitation, bloated |
| Undetermined frequency (cannot be<br>estimated from the available data):             | Penile prolapse <sup>a</sup><br>Loose stool <sup>d</sup> , rumen atony<br>Snoring<br>Premature parturition, uterine disorder <sup>e</sup><br>Polyuria                                                                                                                |

<sup>a</sup> Reversible.

<sup>b</sup> Depending on the ambient temperature.

<sup>c</sup> Atony.

<sup>d</sup> For 24 hours, after high doses of xylazine.

<sup>e</sup> Reduced implantation of the ovum.

Horses:

|                                                                                |                                                                                                                                                                                                                                                                           |
|--------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Rare<br>(1 to 10 animals / 10,000 animals treated):                            | Abnormal behaviour <sup>a</sup><br>Hypothermia <sup>b</sup><br>Hypotension <sup>c</sup>                                                                                                                                                                                   |
| Very rare<br>(<1 animal / 10,000 animals treated, including isolated reports): | Bradycardia (severe), arrhythmia <sup>d</sup><br>Hyperthermia <sup>b</sup><br>Respiratory depression, respiratory arrest<br>Increased sweating <sup>e</sup><br>Muscle tremor, ataxia<br>Colic (mild) <sup>f</sup> , digestive tract hypomotility (temporary) <sup>f</sup> |
| Undetermined frequency<br>(cannot be estimated from the available data):       | Penile prolapse <sup>d</sup><br>Hypertension <sup>c</sup><br>Involuntary movement <sup>g</sup><br>Decreased respiratory rate<br>Frequent urination                                                                                                                        |

<sup>a</sup> Violent reactions have been reported following the administration of xylazine.

<sup>b</sup> Depending on the ambient temperature.

<sup>c</sup> Transient rise in blood pressure, followed by a fall in blood pressure usually occurs.

<sup>d</sup> Reversible.

<sup>e</sup> When the effects of the sedation are wearing off.

<sup>f</sup> As a preventive measure the horse should receive no feed after sedation until the effect has faded completely.

<sup>g</sup> In response to sharp auditory or physical stimuli.

Reporting adverse events is important. It allows continuous safety monitoring of a veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to either the marketing authorisation holder or its local representative or the national competent authority via the national reporting system. See the package leaflet for respective contact details.

### 3.7 Use during pregnancy, lactation or lay

#### Pregnancy and lactation:

Laboratory studies in rats have not produced any evidence of teratogenic or foetotoxic effects. The use of the veterinary medicinal product during the first two trimesters of pregnancy should only be made according to the benefit-risk assessment by the responsible veterinarian.

Do not use in the later stages of pregnancy (particularly in cattle) except at parturition, because xylazine causes uterine contractions and it may induce premature labour.

Do not use in cattle receiving ovum transplants as the increased uterine tone may reduce the chance of implantation of the ovum.

### 3.8 Interaction with other medicinal products and other forms of interaction

Other CNS depressant agents (barbiturates, narcotics, anaesthetics, tranquillizers, etc.) may cause additive CNS depression if used with xylazine. Dosages of these agents may need to be reduced. Xylazine should therefore be used cautiously in combination with neuroleptics or tranquillizers.

Xylazine should not be used in combination with sympathomimetic drugs such as epinephrine as ventricular arrhythmia may follow.

The concurrent intravenous use of potentiated sulphonamides with alpha-2 agonists has been reported to cause cardiac arrhythmias which may be fatal. Whilst no such effects have been reported with this veterinary medicinal product, it is recommended that intravenous administration of trimethoprim/sulphonamide containing veterinary medicinal products should not be undertaken when horses have been sedated with xylazine.

### 3.9 Administration routes and dosage

Cattle: intramuscular use.

Horses: intravenous use.

To ensure a correct dosage, body weight should be determined as accurately as possible.

The intravenous injection to horses should be given slowly.

Cattle:

Dosage:

| Dosage for cattle |                  |                                     |                                     |
|-------------------|------------------|-------------------------------------|-------------------------------------|
| Dosage level*     | xylazine (mg/kg) | Nerfasin vet. 100 mg/ml (ml/100 kg) | Nerfasin vet. 100 mg/ml (ml/500 kg) |
| I                 | 0.05             | 0.05                                | 0.25                                |
| II                | 0.1              | 0.1                                 | 0.5                                 |
| III               | 0.2              | 0.2                                 | 1                                   |
| IV                | 0.3              | 0.3                                 | 1.5                                 |

\*Dose I: Sedation, with a slight decrease of muscle tone. The ability to stand is maintained.

Dose II: Sedation, marked decrease of muscle tone and some analgesia. The animal usually remains standing, but may lie down.

Dose III: Deep sedation, further decrease of muscle tone and a degree of analgesia. The animal lies down.

Dose IV: Very deep sedation, a profound decrease in muscle tone and a degree of analgesia. The animal lies down.

Horses

Dosage: single dose of 0.6 – 1 mg xylazine per kg body weight.

(0.6 – 1 ml of the veterinary medicinal product per 100 kg body weight).

The stopper should not be punctured more than 20 times.

The number of punctures should be recorded on the outer packaging.

### **3.10 Symptoms of overdose (and where applicable, emergency procedures and antidotes)**

In the event of an accidental overdose, cardiac arrhythmias, hypotension, and profound CNS and respiratory depression may occur. Seizures have also been reported after an overdose. Xylazine can be antagonized by  $\alpha$ 2-adrenergic antagonists.

To treat the respiratory depressant effects of xylazine, mechanically respiratory support with or without respiratory stimulants (e.g. doxapram) can be recommended.

### **3.11 Special restrictions for use and special conditions for use, including restrictions on the use of antimicrobial and antiparasitic veterinary medicinal products in order to limit the risk of development of resistance**

### **3.12 Withdrawal periods**

Cattle, horses:  
Meat and offal: 1 day  
Milk: zero hours

## **4. PHARMACOLOGICAL INFORMATION**

### **4.1 ATCvet code: QN05CM92**

### **4.2 Pharmacodynamics**

Xylazine belongs to the  $\alpha$ 2-adrenoceptor agonists.

Xylazine is a  $\alpha$ 2-adrenoceptor agonist, that acts by stimulation of central and peripheral  $\alpha$ 2-adrenoceptors. Through its central stimulation of  $\alpha$ 2-adrenoceptors, xylazine has potent antinociceptive activity. In addition  $\alpha$ 2-adrenergic activity, xylazine has  $\alpha$ 1-adrenergic effects.

Xylazine also produces skeletal muscle relaxation by inhibition of intraneuronal transmission of impulses at the central level of the central nervous system. The analgesic and skeletal muscle relaxation properties of xylazine show considerable interspecies variations. Sufficient analgesia generally will be attained in combination with other veterinary medicinal products only.

In many species, administration of xylazine produces a short-lived arterial pressor effect followed by a longer period of hypotension and bradycardia. These contrasting actions upon the arterial pressure apparently are related to the  $\alpha$ 2- and  $\alpha$ 1-adrenergic actions of xylazine.

Xylazine has several endocrine effects. Insulin (mediated by  $\alpha$ 2-receptors in pancreatic  $\beta$ -cells which inhibit insulin release), ADH (decreased production of ADH, causing polyuria) and FSH (decreased) are reported to be influenced by xylazine.

### **4.3 Pharmacokinetics**

Absorption (and action) is rapid following intramuscular injection. Levels of drug peak rapidly (usually within 15 minutes) and then decline exponentially. Xylazine is a highly lipid soluble organic base and diffuses extensively and rapidly ( $V_d$  1.9 - 2.7). Within minutes after an intravenous injection, it can be found in a high concentration in the kidneys, the liver, the CNS, the hypophyses, and the diaphragm. So there is a very rapid transfer from the blood vessels to the tissues.

Intramuscular bioavailability is incomplete and variable ranging from 40 – 48 % in the horse. Xylazine is metabolised extensively and eliminated rapidly ( $\pm 70$  % via the urine, while the enteric elimination is  $\pm 30$  %). The rapid elimination of xylazine is probably related to an extensive metabolism rather than to a rapid renal excretion of unchanged xylazine.

## **5. PHARMACEUTICAL PARTICULARS**

### **5.1 Major incompatibilities**

In the absence of compatibility studies, this veterinary medicinal product must not be mixed with other veterinary medicinal products.

### **5.2 Shelf life**

Shelf life of the veterinary medicinal product as packaged for sale: 3 years.  
Shelf life after first opening the immediate packaging: 28 days.

### **5.3 Special precautions for storage**

Do not refrigerate or freeze.

### **5.4 Nature and composition of immediate packaging**

10 ml, 30 ml and 50 ml clear type II glass vials closed with a bromobutyl rubber stopper and aluminium cap in a carton box containing 10 ml, 25 ml and 50 ml of the veterinary medicinal product, respectively.

Not all pack sizes may be marketed.

### **5.5 Special precautions for the disposal of unused veterinary medicinal product or waste materials derived from the use of such products**

Medicines should not be disposed of via wastewater.

Use take-back schemes for the disposal of any unused veterinary medicinal product or waste materials derived thereof in accordance with local requirements and with any national collection systems applicable to the veterinary medicinal product concerned.

Any unused product must be disposed of in accordance with the Misuse of Drugs Regulations 2001.

**6. NAME OF THE MARKETING AUTHORISATION HOLDER**

Le Vet B.V.

**7. MARKETING AUTHORISATION NUMBER**

Vm 19994/4018

**8. DATE OF FIRST AUTHORISATION**

15 May 2012

**9. DATE OF THE LAST REVISION OF THE SUMMARY OF THE PRODUCT CHARACTERISTICS**

August 2026

**10. CLASSIFICATION OF VETERINARY MEDICINAL PRODUCT**

Veterinary medicinal product subject to prescription.

Find more product information by searching for the 'Product Information Database' on [www.gov.uk](http://www.gov.uk).

Approved 30 September 2026

*Gavin Hall*